Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

[Risk of fatal/non-fatal events in patients with previous coronary heart disease/acute myocardial infarction and treatment with non-steroidal anti-inflammatory drugs].

Muñoz Olmo L, Juan Armas J, Gomariz García JJ.

Semergen. 2017 Sep 4. pii: S1138-3593(17)30226-5. doi: 10.1016/j.semerg.2017.07.004. [Epub ahead of print] Review. Spanish.

PMID:
28882733
2.

Celecoxib for rheumatoid arthritis.

Fidahic M, Jelicic Kadic A, Radic M, Puljak L.

Cochrane Database Syst Rev. 2017 Jun 9;6:CD012095. doi: 10.1002/14651858.CD012095.pub2. Review.

PMID:
28597983
3.

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.

Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B, Berger MF, Bao W, Lincoff AM; PRECISION Trial Investigators.

N Engl J Med. 2016 Dec 29;375(26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13.

4.

Hepatotoxicity induced by coxibs: how concerned should we be?

Bessone F, Hernandez N, Roma MG, Ridruejo E, Mendizabal M, Medina-Cáliz I, Robles-Díaz M, Lucena MI, Andrade RJ.

Expert Opin Drug Saf. 2016 Nov;15(11):1463-1475. Epub 2016 Aug 26. Review.

PMID:
27537326
5.

Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).

MacDonald TM, Hawkey CJ, Ford I, McMurray JJV, Scheiman JM, Hallas J, Findlay E, Grobbee DE, Hobbs FDR, Ralston SH, Reid DM, Walters MR, Webster J, Ruschitzka F, Ritchie LD, Perez-Gutthann S, Connolly E, Greenlaw N, Wilson A, Wei L, Mackenzie IS.

Eur Heart J. 2017 Jun 14;38(23):1843-1850. doi: 10.1093/eurheartj/ehw387. Erratum in: Eur Heart J. 2016 Dec 24;:.

PMID:
27705888
6.

Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population.

Kim J, Lee J, Shin CM, Lee DH, Park BJ.

BMJ Open Diabetes Res Care. 2015 Dec 18;3(1):e000133. doi: 10.1136/bmjdrc-2015-000133. eCollection 2015.

7.

[Gastrointestinal bleeding].

Lanas Á.

Gastroenterol Hepatol. 2015 Sep;38 Suppl 1:56-63. doi: 10.1016/S0210-5705(15)30020-0. Review. Spanish.

PMID:
26520197
8.

[Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].

De Lossada A, Oteo-Álvaro Á, Giménez S, Oyagüez I, Rejas J.

Semergen. 2016 May-Jun;42(4):235-43. doi: 10.1016/j.semerg.2015.04.008. Epub 2015 May 23. Spanish.

PMID:
26006311
9.

An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.

Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, Liu J, Patterson S, Sinicrope FA, Rodriguez-Bigas MA, Half E, Bulow S, Latchford A, Clark S, Ross WA, Malone B, Hasson H, Richmond E, Hawk E.

Gut. 2016 Feb;65(2):286-95. doi: 10.1136/gutjnl-2014-307235. Epub 2015 Mar 19.

PMID:
25792707
10.

Prevention and Treatment of NSAID Gastropathy.

Gargallo CJ, Sostres C, Lanas A.

Curr Treat Options Gastroenterol. 2014 Dec;12(4):398-413. doi: 10.1007/s11938-014-0029-4.

PMID:
25209136
11.

A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.

Brereton N, Pennington B, Ekelund M, Akehurst R.

J Med Econ. 2014 Sep;17(9):677-84. doi: 10.3111/13696998.2014.933111. Epub 2014 Jun 30.

PMID:
24914585
12.

Efficiency of naproxen/esomeprazole in association for osteoarthrosis treatment in Spain.

Capel M, Tornero J, Zamorano JL, Oyagüez I, Casado MÁ, Sánchez-Covisa J, Lanas A.

Reumatol Clin. 2014 Jul-Aug;10(4):210-7. doi: 10.1016/j.reuma.2013.11.009. Epub 2013 Dec 29. English, Spanish.

13.

Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.

Wielage R, Bansal M, Wilson K, Klein R, Happich M.

Spine (Phila Pa 1976). 2013 May 15;38(11):936-46. doi: 10.1097/BRS.0b013e31828264f9.

PMID:
23250234
14.

A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893.

Felgenhauer JL, Nieder ML, Krailo MD, Bernstein ML, Henry DW, Malkin D, Baruchel S, Chuba PJ, Sailer SL, Brown K, Ranganathan S, Marina N.

Pediatr Blood Cancer. 2013 Mar;60(3):409-14. doi: 10.1002/pbc.24328. Epub 2012 Oct 12.

15.

Celecoxib induces heme oxygenase-1 expression in macrophages and vascular smooth muscle cells via ROS-dependent signaling pathway.

Wang JS, Ho FM, Kang HC, Lin WW, Huang KC.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Feb;383(2):159-68. doi: 10.1007/s00210-010-0586-6. Epub 2010 Dec 22.

PMID:
21174079
16.

Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors.

Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG.

Pharmacoeconomics. 2011 Mar;29(3):225-37. doi: 10.2165/11584200-000000000-00000.

PMID:
21062104
17.

Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users.

Laharie D, Droz-Perroteau C, Bénichou J, Amouretti M, Blin P, Bégaud B, Guiard E, Dutoit S, Lamarque S, Moride Y, Depont F, Fourrier-Réglat A, Moore N.

Br J Clin Pharmacol. 2010 Mar;69(3):295-302. doi: 10.1111/j.1365-2125.2009.03588.x.

18.

Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.

Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.

J Med Assoc Thai. 2009 Dec;92 Suppl 6:S19-26.

PMID:
20128070
19.

Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.

Bessette L, Risebrough N, Mittmann N, Roussy JP, Ho J, Zlateva G.

J Med Econ. 2009 Sep;12(3):246-58. doi: 10.3111/13696990903288970.

PMID:
19743942
20.

Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.

Roumie CL, Choma NN, Kaltenbach L, Mitchel EF Jr, Arbogast PG, Griffin MR.

Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1053-63. doi: 10.1002/pds.1820.

PMID:
19637402

Supplemental Content

Loading ...
Support Center